Oral Mucositis - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 95 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Oral Mucositis - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Oral Mucositis - Pipeline Review, H1 2015', provides an overview of the Oral Mucositis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Oral Mucositis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Oral Mucositis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Oral Mucositis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Oral Mucositis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Oral Mucositis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Oral Mucositis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Oral Mucositis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Oral Mucositis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Oral Mucositis Overview 8
Therapeutics Development 9
Pipeline Products for Oral Mucositis - Overview 9
Pipeline Products for Oral Mucositis - Comparative Analysis 10
Oral Mucositis - Therapeutics under Development by Companies 11
Oral Mucositis - Therapeutics under Investigation by Universities/Institutes 13
Oral Mucositis - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Oral Mucositis - Products under Development by Companies 17
Oral Mucositis - Products under Investigation by Universities/Institutes 18
Oral Mucositis - Companies Involved in Therapeutics Development 19
ActogeniX NV 19
Alder Biopharmaceuticals Inc. 20
Cellceutix Corporation 21
Colby Pharmaceutical Company 22
Daewoong Pharmaceutical Co., Ltd. 23
GliaMed, Inc. 24
Laila Pharmaceuticals Pvt. Ltd. 25
Onxeo SA 26
Otsuka Holdings Co., Ltd. 27
ProCertus BioPharm Inc. 28
Soligenix, Inc. 29
Spectrum Pharmaceuticals, Inc. 30
Sucampo Pharmaceuticals, Inc. 31
Oral Mucositis - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
AG-013 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
AP-001 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
AP-002 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
brilacidin - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
clazakizumab - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
clonidine hydrochloride ER - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
cobiprostone - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
GC-4403 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
GC-4419 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Gene Therapy for Oral Mucositis - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
GM-1485 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
JVRSOD - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
LP-00409 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
nepidermin - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
OralX - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
pralatrexate - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
rebamipide - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Regenasyn - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
SGX-942 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Oral Mucositis - Recent Pipeline Updates 68
Oral Mucositis - Dormant Projects 85
Oral Mucositis - Discontinued Products 86
Oral Mucositis - Product Development Milestones 87
Featured News & Press Releases 87
Jan 05, 2015: Soligenix Announces Positive Preliminary Nonclinical Results in Macrophage Activation Syndrome 87
Dec 08, 2014: Cellceutix Antibiotic Brilacidin Receives QIDP Designation From FDA 87
Nov 24, 2014: Cellceutix Provides Update On lead drug candidate Brilacidin 88
Nov 11, 2014: Patient Enrollment in Cellceutix Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis Targeted to Begin in December 2014 88
Oct 13, 2014: Cellceutix Investigational New Drug Application Becomes Effective, Selects First Site for Phase 2 Clinical Trial of New Treatment for Oral Mucositis 89
Sep 09, 2014: Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis 90
Aug 11, 2014: Cellceutix Prepares for Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis 91
May 05, 2014: BioAlliance Pharma announces major achievements on Validive: Enrollment completion in the international Phase II trial with Validive in severe oral mucositis, Presentation of preclinical data at the next ASCO annual meeting 92
Apr 07, 2014: Soligenix Announces $200,000 NIDCR SBIR Grant Award Supporting Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer 92
Jan 23, 2014: FDA Grants Validive with a Fast Track Designation for the Prevention and Treatment of Oral Mucositis Induced by Anticancer Treatments 93
Appendix 94
Methodology 94
Coverage 94
Secondary Research 94
Primary Research 94
Expert Panel Validation 94
Contact Us 95
Disclaimer 95

List of Tables
Number of Products under Development for Oral Mucositis, H1 2015 9
Number of Products under Development for Oral Mucositis - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Late Stage Development, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Products under Investigation by Universities/Institutes, H1 2015 18
Oral Mucositis - Pipeline by ActogeniX NV, H1 2015 19
Oral Mucositis - Pipeline by Alder Biopharmaceuticals Inc., H1 2015 20
Oral Mucositis - Pipeline by Cellceutix Corporation, H1 2015 21
Oral Mucositis - Pipeline by Colby Pharmaceutical Company, H1 2015 22
Oral Mucositis - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 23
Oral Mucositis - Pipeline by GliaMed, Inc., H1 2015 24
Oral Mucositis - Pipeline by Laila Pharmaceuticals Pvt. Ltd., H1 2015 25
Oral Mucositis - Pipeline by Onxeo SA, H1 2015 26
Oral Mucositis - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 27
Oral Mucositis - Pipeline by ProCertus BioPharm Inc., H1 2015 28
Oral Mucositis - Pipeline by Soligenix, Inc., H1 2015 29
Oral Mucositis - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015 30
Oral Mucositis - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2015 31
Assessment by Monotherapy Products, H1 2015 32
Number of Products by Stage and Target, H1 2015 34
Number of Products by Stage and Mechanism of Action, H1 2015 36
Number of Products by Stage and Route of Administration, H1 2015 38
Number of Products by Stage and Molecule Type, H1 2015 40
Oral Mucositis Therapeutics - Recent Pipeline Updates, H1 2015 68
Oral Mucositis - Dormant Projects, H1 2015 85
Oral Mucositis - Discontinued Products, H1 2015 86